Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells - Wikidata - awgldk - TriplyDB

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells

http://www.wikidata.org/entity/Q37698914

about

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.The making of bispecific antibodies Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Targeting Phosphatidylserine with Calcium-Dependent Protein-Drug Conjugates for the Treatment of Cancer.

P2860

Q33691823-8D7082DE-5BE3-4423-A920-785217C27465 Q34506951-9B701CAA-0B7D-4FB9-83DB-4F7A18257B22 Q36987701-B158DAA4-697C-4233-968C-ED2A20DC43E6 Q37716375-D7D485B6-EC6A-4CB7-A4EA-F124300FC367 Q38623361-E5EA3788-5068-41A8-979C-88DE586BF6C5 Q38768387-CEDCB09D-8CBC-4A40-9055-5574198537A5 Q38770505-8D470348-935C-4BBD-A338-9FE609AE44D1 Q38812867-5CFB8763-0FB3-4ADD-BAA3-9A5A8D2F54A9 Q38929801-95F9668B-0CF3-4730-89F4-DF6846450772 Q38932495-9E7F01B3-AFA2-4764-A968-21828853E3AA Q40176588-A3257139-BE96-4D8F-9550-108D34A8F9AF Q42323236-73B77E2F-FCCC-42C5-A5C9-F3F3E2AD0AF1 Q42660142-7D748C5E-B52F-477F-AD42-CB79F446BDB1 Q47319293-4DDCCB98-87C5-4D1E-8E1F-8E4215EE0FB5

P2860

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells

http://www.wikidata.org/entity/Q37698914

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Engineering multivalent antibo ...... gnaling in breast cancer cells

@en

Engineering multivalent antibo ...... naling in breast cancer cells.

@nl

type

label

Engineering multivalent antibo ...... gnaling in breast cancer cells

@en

Engineering multivalent antibo ...... naling in breast cancer cells.

@nl

prefLabel

Engineering multivalent antibo ...... gnaling in breast cancer cells

@en

Engineering multivalent antibo ...... naling in breast cancer cells.

@nl

P1433

Q37698914-5120E903-1AF4-489E-984B-EE8CB340E0C1

P1476

Q37698914-3B6FE10B-3A53-412E-8B90-E027183ABEF6

P2093

Q37698914-0A0651FC-FECC-4412-B249-1AAEDE4F5E3D

Q37698914-2F5EC1B6-0C79-4753-A7B4-D59A3D967B99

Q37698914-393DBB2E-0BE5-4A0C-9687-FE2958D27738

Q37698914-5CCF1751-B9D4-42B1-A5A7-8A69F55EF477

Q37698914-D881876B-E48D-4DD6-8CE1-E916F19292A8

P2860

Q37698914-06ADEB28-3CD7-4E41-8254-51E4ED6234D0

Q37698914-093BFDCD-6873-4493-A1BF-79DC1E13BF21

Q37698914-0BE07C53-D12C-4171-AEE4-9419240A4FAA

Q37698914-11D4EBBB-1948-4FCF-90CB-86ED84E3E99C

Q37698914-14FA149F-E8C8-4D26-86F9-47888A1BA7C0

Q37698914-1ADB0265-5373-4F4F-BB63-83B1D61C12AE

Q37698914-1C4E5637-F762-444E-AAE9-D8A9A62AD0E8

Q37698914-1C67C894-B0B6-48E5-8FCE-5D7DBDB1F4F4

Q37698914-1EC53884-0B8D-4052-A2E4-C6F2E4A0E395

Q37698914-1F5556F4-2AE4-459A-97C8-1DEC38354ABC

P304

Q37698914-7E4D0656-74BE-4D1C-A4DC-2BB6816D3820

P31

Q37698914-E7D34620-E6BC-45FA-9735-9160C347A1DB

P356

Q37698914-E4F0E77E-2029-4EA8-A61C-988361E9B4F7

P433

Q37698914-BFBF11A3-2CA8-451A-9FE1-A8A2FA54D29C

P478

Q37698914-3FE3AC18-8E92-4C95-BC42-0A518E078EB7

P50

Q37698914-45C17EDF-7B5A-48AB-B765-2F7CF803ECAD

Q37698914-D23CCAB1-D9F7-43D6-A08F-9C5EC99D5CF5

P577

Q37698914-4B8131CA-D763-47B8-A220-85E140AE0F68

P5875

Q37698914-5991A68B-A3A2-4793-80D3-B645F71BE002

P698

Q37698914-553B29F2-A686-429E-8F20-3C72E890766A

P921

Q37698914-3B992ECA-583B-4ABE-B84C-C4488BC3BD49

P932

Q37698914-DCFD9DEF-4926-43C7-88DA-D45AEC734C0C

P356

P1433

Monoclonal Antibodies

P1476

Engineering multivalent antibo ...... gnaling in breast cancer cells

@en

P2093

Isabel M Manjarres

http://www.w3.org/2001/XMLSchema#string

Jayakumar S Poovassery

http://www.w3.org/2001/XMLSchema#string

Jeffrey C Kang

http://www.w3.org/2001/XMLSchema#string

Pankaj Bansal

http://www.w3.org/2001/XMLSchema#string

Sungyong You

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Humanization of an anti-p185HER2 antibody for human cancer therapy

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

340-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.27658

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260090365

http://www.w3.org/2001/XMLSchema#string

P698

24492289

http://www.w3.org/2001/XMLSchema#string

P921

P932

3984324

http://www.w3.org/2001/XMLSchema#string